46 news items
Page 2 of 3
d5je2m g1sbb
BMY
16 May 24
Following four years of continuous Sotyktu treatment, clinical response was maintained in more
ncx6ufkwhn16bsifcniksvg50qb e2
BMY
16 May 24
four years of continuous Sotyktu treatment, clinical response was maintained in more than seven out of 10
llh1gsme95s69csagjkms 63uzowmvc
BMY
15 May 24
with median duration of response not reached and the majority (77.1%) of responders in ongoing response at 18 months
ejhewazpqcmz700k1fzz74cbdxbpba6
BMY
10 May 24
overall survival (OS) across the study arms, PFS by RECIST 1.1 per BICR across the study arms, as well as objective response rate (ORR), time
7v8tjp bp
BMY
29 Apr 24
, it will deploy DECODE to monitor immune responses to the tolerizing vaccines in patients during clinical development to provide key insights
k6rkymjwrptx7l1eykl96hzx o4kdykamdfebc
BMY
26 Apr 24
', or 'Lower' their stance, it signifies their response to recent developments related to Bristol-Myers Squibb. This offers insight into analysts' perspectives
t97xh3l4 0cl
BMY
26 Apr 24
of care for decades but the durability of response to chemotherapy alone is poor and once a patient progresses, treatment options become increasingly
5hue2u4vsromowjgm35
BMY
25 Apr 24
response
c1srww
AGEN
BMY
12 Apr 24
response rate (ORR) was observed after a median follow up of 13.6 months at the data cutoff of March 1, 2024.
The median duration
ij7u3njz78cite2gbz2df8 z2lv3wzzyx7k28gkr3aef736pu38yz3gs6an
BMY
JNJ
MRK
10 Apr 24
continues to build its heart business.
Johnson & Johnson is focusing on enhancing its cardiovascular health business in response to its
d337tgtullfahguxh91fg90 zt81n2r
BMY
8 Apr 24
.
With a median follow-up of 11.9 months in 94 patients, Krazati plus cetuximab demonstrated an objective response rate, the primary endpoint, of 34%, median
r3gcak9p
BMY
TSVT
5 Apr 24
showed a significant improvement in overall response rates (p<0.0001) with the majority (71%) of patients treated
ckvr6isf8h8h johm2r
BMY
IRON
VERV
4 Apr 24
with ring sideroblasts, who had an unsatisfactory response to or are ineligible for erythropoietin-based therapy. It is also indicated for the treatment
i12gomds1nh824wy9jtd9 jliwclb
BMY
LAB
3 Apr 24
on the development of these new tools that will accelerate insights into disease response," says Michael Egholm, President and Chief Executive Officer
ru3ko3phui6mn1149ccdpbpwo1t0in2lkrfwdu72ee6
BMY
2 Apr 24
.
"In the treatment of lower-risk MDS, few patients experience a lasting response to erythroid stimulating agents, leaving a critical need for more